J

Johnson & Johnson

Makes prescription drugs and medical devices

Senior Principal Engineer - Aseptic DP Compounding Owner, Aseptic DP Compounding

Full-TimeUpdated on 10/23/2026Deadline 10/30/26
No salary listed
Expert
Bachelor's, Master's, MBA
Wilson, NC, USA
In PersonFull-time onsite in Wilson, NC; frequent travel (>75%) to the engineering firm is required until the project shifts to the plant site.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • A Bachelor's degree in engineering is required; Chemical Engineering is preferred. A Master's degree or MBA is preferred.
  • At least 10 years of experience in aseptic drug product compounding in a biotherapeutics current Good Manufacturing Practice environment, preferably in process engineering or capital project execution.
  • A track record of developing and maintaining strong partnerships with key stakeholders.
  • Experience designing and implementing single-use technology, including single-use mixers and single-use product paths.
  • Experience designing stainless steel tanks and developing cleaning and sterilization recipes for stainless steel tanks.
  • Ability to lead and motivate multicultural teams and remote customers.
  • Extensive experience interacting with external engineering firms, construction firms, and equipment vendors to develop, organize, and execute project plans as the aseptic drug product biotherapeutic compounding subject matter expert.
  • Strong problem-solving skills when handling potential conflicts.
  • Understanding of sophisticated technical and regulatory issues that affect facility and equipment design.
  • A solid understanding of current Good Manufacturing Practices for biotherapeutics drug product aseptic compounding.
  • A solid understanding of environmental, health, and safety requirements, particularly safety by design and construction safety.
  • A solid understanding of single-use technology design, including mixers and product fluid paths.
  • A solid understanding of start-up processes and commissioning and qualification of compounding equipment.
  • A solid understanding of engineering design principles for drug products in the biotherapeutic industry.
  • A solid understanding of construction and procurement processes, project controls processes, and project scheduling.
  • Strong technical process engineering knowledge and experience.
  • Strong problem-solving, communication, and decision-making skills to drive impact in a fast-paced, evolving business environment.
  • Ability to drive process engineering innovation for equipment and facilities and ensure technical knowledge is maintained and expanded throughout the team.
Responsibilities
  • Develop and deliver specifications and drawings for aseptic biotherapeutic drug product compounding equipment, including single-use mixers, stainless steel tanks, clean-out-of-place skids, sterilize-out-of-place skids, mixing, and filter integrity testing; produce user requirements, data sheets, technical specifications, piping and instrumentation diagrams, and process flow diagrams.
  • Assess vendor competency and capabilities, review and discuss bid documents, and take accountability for project development and execution, including process-system performance.
  • Lead detailed design and development of two aseptic drug product compounding suites, processes, equipment, and recipes in collaboration with a multifunctional team and strategic equipment vendors.
  • Lead equipment factory acceptance testing, site acceptance testing, commissioning and qualification, and start-up.
  • Resolve technical issues on the system during commissioning and qualification testing and ensure system readiness for those activities.
  • Identify and expedite key activities across Manufacturing, Facilities, Manufacturing Science and Technology, Quality, Procurement, Engineering and Property Services, and Environmental, Health and Safety.
  • Ensure alignment across evolving business needs and collaborate with multiple business partners.
  • Maintain understanding of industry trends and benchmark against internal and external practices.
  • Apply data-driven insights and market intelligence to advise future decisions, stay informed about industry and regulatory trends, and adapt strategies to achieve portfolio performance.
  • Ensure compliance with policies, procedures, government regulations, and customer specifications.
  • Provide full-time onsite support at the Wilson, North Carolina location; travel frequently (more than 75%) to an engineering firm during facility design until the project shifts to the Wilson plant site.
Desired Qualifications
  • A consistent track record leading capital projects for biotherapeutic aseptic drug product compounding equipment and automating compounding equipment in the $30–$50 million range.
  • Strong process engineering expertise from conceptual design through commissioning and qualification to ensure operational readiness in an aseptic biotherapeutic drug product environment.
  • Experience starting up greenfield or brownfield Good Manufacturing Practice facilities.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.

Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.